QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

被引：0
|
作者：
P Ghatalia
Y Je
M D Kaymakcalan
G Sonpavde
T K Choueiri
机构：
[1] University of Alabama at Birmingham (UAB),Department of Internal Medicine
[2] Kyung Hee University,Department of Food and Nutrition
[3] Dana Farber Cancer Institute and Harvard Medical School,Department of Internal Medicine
[4] Section of Medical Oncology,undefined
[5] UAB Medical Center,undefined
来源：
British Journal of Cancer | 2015年 / 112卷
关键词：
vascular endothelial growth factor receptor; tyrosine kinase inhibitors; approved; QTc interval prolongation; meta-analysis; cardiac toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：296 / 305
页数：9
相关论文
共 50 条
  • [31] Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition
    Masuo, Yusuke
    Fujita, Ken-ichi
    Shimada, Kazuhiro
    Iida, Noriho
    Wakayama, Tomohiko
    Kato, Yukio
    Alshammari, Aya Hasan
    BIOCHEMICAL PHARMACOLOGY, 2022, 197
  • [32] Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: An overview
    Normanno, N
    Maiello, MR
    Mancino, M
    De Luca, A
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 36 - 40
  • [33] Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors
    Hirsh, V.
    Blais, N.
    Burkes, R.
    Verma, S.
    Croitoru, K.
    CURRENT ONCOLOGY, 2014, 21 (06) : 329 - 336
  • [34] RETRACTED: Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials (Retracted Article)
    Hong, Shaodong
    Fang, Wenfeng
    Liang, Wenhua
    Yan, Yue
    Zhou, Ting
    Qin, Tao
    Wu, Xuan
    Ma, Yuxiang
    Zhao, Yuanyuan
    Yang, Yunpeng
    Hu, Zhihuang
    Xue, Cong
    Hou, Xue
    Chen, Yue
    Huang, Yan
    Zhao, Hongyun
    Zhang, Li
    ONCOTARGETS AND THERAPY, 2014, 7 : 1851 - 1867
  • [35] Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials
    Yimaer, Wufuer
    Abudouyimu, Aizizi
    Tian, Ye
    Magaoweiya, Sailike
    Bagedati, Duman
    Wen, Hao
    ONCOTARGETS AND THERAPY, 2016, 9 : 1167 - 1173
  • [36] Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis
    Li, Jing
    Gu, Jian
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (05) : 807 - 816
  • [37] Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis
    Jing Li
    Jian Gu
    International Journal of Clinical Oncology, 2017, 22 : 807 - 816
  • [38] High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor
    Pouessel, Damien
    Culine, Stephane
    EUROPEAN UROLOGY, 2008, 53 (02) : 376 - 381
  • [39] The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
    Eskens, Ferry A. L. M.
    Verweij, Jaap
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (18) : 3127 - 3139
  • [40] Discovery of Potent Vascular Endothelial Growth Factor Receptor-2 Inhibitors
    Papakyriakou, Athanasios
    Katsarou, Maria E.
    Belimezi, Maria
    Karpusas, Michael
    Vourloumis, Dionisios
    CHEMMEDCHEM, 2010, 5 (01) : 118 - 129
12345